CCR9 antagonism: potential in the treatment of Inflammatory Bowel Disease

Emily Wendt
Satish Keshav

Translational Gastroenterology Unit, Nuffield Department of Medicine, John Radcliffe Hospital, Oxford, UK

Correspondence: Satish Keshav
Gastroenterology Unit, Nuffield Department of Medicine, Level 5, John Radcliffe Hospital, Headley Way, Oxford, OX3 9DU, UK
Tel +44 18 6522 8759
Fax +44 18 6522 8763
Email satish.keshav@ndm.ox.ac.uk

Abstract: Inflammatory Bowel Disease (IBD), mainly comprising Crohn’s disease (CD) and ulcerative colitis (UC), is a chronic condition that primarily affects the intestine and is characterized by leukocytic infiltration. Blocking the migration of leukocytes from the circulation is therefore a reasonable therapeutic goal. Recent clinical trials using this approach have shown promise, with the monoclonal antibody to α4β7 integrin, vedolizumab, and previously with the monoclonal antibody to the α4 subunit, natalizumab. Directly targeting the subset of α4β7 expressing cells that co-express CC chemokine receptor 9 (CCR9), using the orally administered antagonist, CCX282-B, also known as vencerinor, has also been evaluated in Phase II and III trials that have produced mixed results. Although CCX282-B showed efficacy in inducing response in active CD in early studies, this was not confirmed in a Phase III study. CCX282-B was also more effective than placebo in maintaining remission, and this result has yet to be confirmed in Phase III. The efficacy of blocking CCR9 in UC, where vedolizumab was effective, has not been tested. The prospect of targeting CCR9 in IBD remains attractive. Much of the local accumulation of inflammatory cells in the intestine arises from migration rather than local proliferation and genetic and pharmacological targeting of CCR9 or its ligand in preclinical models that mimic UC and CD ameliorate inflammation in some cases. Furthermore, binding of chemokine ligands to receptor is a critical step in activating integrin binding, so there is a potential for synergistic action between integrin and chemokine antagonists. CCR9 is expressed on a smaller proportion of circulating cells than α4β7 integrin, which may offer greater specificity of effect, particularly in long term use. Furthermore, while α4β7 is widely expressed on T and B cell subsets, CCR9 is mainly expressed on effector memory Th1 cells. Indications for the use of intestine-specific integrin and chemokine receptor targeting may also extend beyond IBD, to include, for example, postoperative ileus, and primary sclerosing cholangitis.

Keywords: Crohn’s disease, ulcerative colitis, CCL25, CCX282-B, Traficet-EN, GSK10605786, CC chemokine receptor 9

Introduction

Inflammatory Bowel Disease (IBD) is a chronic condition comprising mainly two subgroups: Crohn’s disease (CD) and ulcerative colitis (UC), distinguished by clinical, endoscopic, and pathological features that overlap to some extent. Approximately 2.2 million Europeans and 1.4 million North Americans are affected by IBD, with rising incidence and prevalence in Westernized nations.1,2 IBD occurs equally in both sexes, and the incidence is highest in the second to fourth decades of life, affecting people at the prime of their economic and reproductive lives.3,4 IBD is characterized by leukocytic infiltration in the intestinal mucosa; chemokine receptors and their
cognate chemokine ligands contribute to inflammation by
mediating the directional migration of cells, in for instance,
extravasation of cells from the circulation into tissues.4,5
Intestine specific homing molecules such as CC chemokine
receptor 9 (CCR9) and its ligand, CC ligand 25 (CCL25) are
targets amenable to the development of blocking drugs. In
this review, we highlight pertinent differences between CD
and UC, review what is known about CCR9 in the context of
homeostatic and inflammatory recruitment to the intestine,
and discuss preclinical and clinical data on the use of CCR9
antagonists in IBD.

Pathology and immunophenotype in CD and UC
CD can affect any part of the gastrointestinal tract, from
mouth to anus, and in the majority of cases (∼80%) includes
inflammation of the distal small intestine; roughly 60% of
patients with CD will also have inflammation of the colon.6
Intestinal lesions manifest in patches, with inflamed tissue
adjacent to healthy or quiescent mucosa. CD is also associ-
ated with granulomas, strictures and fistulas, features that
are not typically present in UC.7,8 Histological evaluation
reveals an accumulation of leukocytes in the lamina propria
(LP), and inflammatory cells penetrating deep into the sub-
mucosal layers. Prolonged or extensive inflammation changes
the intestinal architecture, expanding the LP and causing
thickened, distorted villi.

Although infiltrating cells are heterogeneous, and the
cell population promoting inflammation is still debated, CD
shows many features of a Th1 type inflammatory condi-
tion.3,9–11 This is on the basis of work since the early 1990s,
demonstrating that CD lesions have elevated expression of
Th1 associated cytokines.11–15 Th1 cells are a subgroup of
CD4+ T helper cells that primarily secrete interferon (IFN)-
γ, and are polarized toward a Th1 phenotype by the action of
interleukin (IL)-12 through the transcription factor T-bet.16
Th1 cells have a critical role in host defense against intracellu-
lar pathogens including viruses and bacteria, although an
exacerbated Th1 response is deleterious, as demonstrated by
the Th1 response caused by Mycobacterium tuberculosis.
Indeed, pathologically, CD can be hard to distinguish from
intestinal tuberculosis.

A Th1 rich cytokine environment is not a general feature of
IBD; in inflamed lesions in UC, undetectable or low levels
of IFN-γ have been reported.10,13 Th2 associated cytokines,
including IL-5 and IL-13 are often over-expressed.10,17,18 Th2
cells are CD4+ T helper cells that have a role in host defense
against extracellular pathogens including parasites, and are
regulated by the transcription factor GATA3.19 They also
play an important role in humoral immunity; IL-5 and IL-13
stimulate B cell class switching and antibody production.
In UC, inflammation is confined to the colon, presenting as
superficial and continuous ulceration, usually involving the
rectum (proctitis) and extending proximally in the colon for
a variable distance. The majority of patients (∼80%) have
limited, distal colitis or proctitis, and ~20% have inflamm-
tion of the entire colon, or pan-colitis.6

The Th17 pathway is implicated in both CD and UC. Th17
polarized CD4+ T helper cells produce IL-17A, IL-17F, and
IL-22, and are regulated by the transcription factor RORγ.20
IL-17 is a neutrophil chemo-attractant, critical in host defense
against extracellular infections and potentially deleterious
when excessively produced.21 Genome-wide association studies
implicate polymorphisms in the IL-23 receptor, which is neces-
sary to promote differentiation of Th17 cells, as a risk factor for
both UC and CD, as well as other autoimmune diseases.22

Current therapies in IBD
Treating CD
Patients with CD vary greatly in the severity and natural
behavior of disease, age of onset, and localization of inflam-
mation, which is partly captured in the widely used Montreal
classification.23 The treatment of CD must be adapted and
individualized to match this complexity, and in some cases,
such as isolated ileal CD with structuring, primary surgical
resection with subsequent secondary prevention using
medications may be most appropriate. In other cases, pri-
mary medical treatment may be more appropriate, and there
are indications that early use of powerful treatments may
alter the natural history of disease and reduce long-term
complications. In acute inflammatory CD, systemic corticos-
teroids and anti-tumour necrosis factor (TNF) antibodies are
effective at inducing a response in the majority of cases while
5-aminosalicylate (5-ASA) compounds are ineffective.24

Maintaining remission in CD relies on the use of immu-
nosuppressants, primarily thiopurines or methotrexate.
Anti-TNF agents such as infliximab and adalimumab are
also effective, and are generally used where patients do not
respond to orally administered immunosuppressants. Trials
with the antibody to α4 integrin, natalizumab, showed effi-
cacy in inducing and maintaining clinical response, although
natalizumab is not widely used for this indication because of
the risk of reactivation of JC virus infection, with potentially
fatal consequences.25,26

Newer treatments for CD include the use of antibodies to
IL-12/IL-23, such as ustekinumab, and antibody treatment
against integrin, \( \alpha_\beta \), vedolizumab.\textsuperscript{27,28} The clinical effect of vedolizumab in inducing clinical response in active CD was modest, although maintenance treatment demonstrated sustained benefit.\textsuperscript{27} These emerging data demonstrate the complexity of CD, and support the hypothesis that lymphocyte migration to the intestine contributes to disease and treatments targeting more specific cell populations may offer therapeutic benefits when administered in the appropriate context, such as maintenance versus induction of response.

**Treating UC**

The mainstay of treatment of UC is 5-ASA, which can be administered topically in the distal colon or rectum, and orally in a variety of formulations that limit systemic absorption in the small intestine and provide maximum exposure to the colonic mucosa.\textsuperscript{29} The aforementioned treatment is effective in inducing response in active disease, and maintaining remission in the chronic phase. Toxicity and side-effects are minimal, partly because of the low systemic exposure. When 5-ASA are inadequate to treat patients with UC, topical and systemic corticosteroids are effective and are widely used to induce response in active disease.\textsuperscript{30} However, they are unsuited for long-term maintenance treatment because of the risk of side-effects, many of which are dose- and duration-dependent, and potentially serious, such as osteoporosis, steroid-induced diabetes, and increased body mass index.

To maintain remission in cases where 5-ASA are insufficient, most patients are treated with immunosuppressants such as azathioprine, mercaptopurine, methotrexate, and tacrolimus.\textsuperscript{31,32} In the UK and USA, the greatest experience is with the use of thiopurines, azathioprine and mercaptopurine (6-MP), and approximately 40% of patients with UC are treated with these drugs.\textsuperscript{31} Side effects from thiopurines are infrequent, although they can be serious and life threatening. They include bone marrow suppression, increased susceptibility to serious viral infections such as herpes simplex virus (HSV), Epstein–Barr virus (EBV), and cytomegalovirus (CMV), increased risk of lymphoma, and idiopathic inflammation including pancreatitis.\textsuperscript{33} In cases refractory to steroids and thiopurines, anti-TNF antibodies such as infliximab, adalimumab, and recently golimumab, have been shown to be effective in inducing and maintaining response in a proportion of cases.\textsuperscript{34} Most recently, the anti-integrin antibody, vedolizumab has also been shown to be effective in patients with UC who do not respond to the established treatments.\textsuperscript{35}

In acute severe colitis (ASC), which presents with high stool frequency, rectal bleeding, and evidence of systemic inflammation, patients are hospitalized for treatment as the condition carries a risk of fatality, and a substantial risk of requiring a colectomy to treat medically uncontrollable colonic inflammation.\textsuperscript{36} The standard treatment of ASC includes high dose intravenous corticosteroid. Approximately 70% of patients respond clinically to this treatment. However, where this is ineffective, it is appropriate to consider colectomy or additional immunosuppression. The standard options in this situation are intravenous or oral cyclosporine, or intravenous infliximab and the efficacy of these treatments appears to be equal.\textsuperscript{37} However, in the longer term, approximately 40% of patients with ASC undergo colectomy, even if they initially have a clinical response to cyclosporine or infliximab. Newer agents such as vedolizumab have not yet been tested in the context of ASC.

Treatments to suppress the immune response show varying degrees of success in IBD, however there remains an unmet need for more targeted treatments, both to induce response in active disease, and to maintain remission potentially for decades without risking side effects, especially those arising from sustained general immune suppression. Furthermore, while many new treatments are based on therapeutic antibodies, there is a need for more cost-effective treatments that potentially could be produced more cheaply, and administered orally.

**Intestine specific homing versus in situ proliferation**

Active IBD is characterized by an accumulation of immune cells in the intestinal mucosa, including effector T cells. Effector T cells are thought to have a key role in disease through their cytotoxic activity and pro-inflammatory cytokine production.\textsuperscript{38,39} Strikingly, few T cells are actively proliferating in the human intestine; Fell et al demonstrated by immunohistochemical staining for Ki67 (marker of cell proliferation), that less than 1.5% of LP and follicular CD3\(^+\) T cells are proliferating in active CD and UC.\textsuperscript{40} Therefore, extravasation from the circulation into the tissue, and the retention of LP T cells must play a critical role in their accumulation during IBD. This is in contrast to mice, where models that resemble aspects of IBD, such as the T cell transfer model and dextran sodium sulfate (DSS)-induced colitis, have significant T cell proliferation within the intestinal LP.\textsuperscript{41-43} This is therefore an important difference between IBD and murine models of intestinal inflammation.

Cell extravasation from the peripheral blood into relevant tissue, such as the intestine, is a tightly regulated process,
mediated by members of the selectin, integrin, and chemokine protein families (Figure 1). Integrins are dimeric surface receptors composed of $\alpha$ and $\beta$ subunits that bind adhesion molecules to promote the firm adhesion of leukocytes to the vascular endothelium. On circulating cells, integrins remain in an inactive conformation, and in response to inflammatory mediators and chemokines, rapidly undergo conformational changes that activate their capacity for tight adhesion. Integrins are chemoattractant cytokines that bind cognate chemokine receptors expressed on the surface of leukocytes. In addition to providing a chemotactic signal, chemokines facilitate integrin activation.

The particular combination of surface integrins and chemokine receptors coordinate the movement of leukocytes to appropriate tissues. For example, T cells that express CCR4 and/or CCR10 in combination with cutaneous lymphocyte antigen have a characteristic skin homing phenotype. Cells that express CCR9 and integrin $\alpha_4\beta_7$ preferentially migrate to the intestine. CCR9 interacts with cognate ligand CCL25, predominantly expressed in the small intestinal mucosa. Integrin $\alpha_4\beta_7$, interacts with mucosal addressin cell adhesion molecule-1 (MAdCAM-1) and vascular cell adhesion molecule-1 (VCAM-1) present on mucosal endothelium and activated endothelium respectively.

Naïve T cells activated by dendritic cells situated in intestinal draining lymph nodes are preferentially induced to express CCR9 and integrin $\alpha_4\beta_7$, promoting recirculation to the intestine. Induction of CCR9 and $\alpha_4\beta_7$ expression is at least in part the result of exposure to the vitamin A metabolite, retinoic acid (RA). Iwata et al identified RA as a potent inducer of CCR9 and $\alpha_4\beta_7$ in vitro and demonstrated that dendritic cells from the gut associated lymphoid tissue express the enzymes necessary to catalyze the production of RA. In vivo, cells expressing CCR9 and $\alpha_4\beta_7$ preferentially migrate to intestinal tissue.

**CCR9 and CCL25 expression in healthy tissue**

In 1997, Vicari et al isolated CCL25 cDNA from the thymus of mice deficient in recombinase activation gene-1 (RAG-1); these mice have smaller lymphoid organs and do not produce mature B and T cells. CCL25 displayed high sequence homology to other members of the CC chemokine family, was found to be a potent chemoattractant for thymocytes, and was therefore designated Thymus Expressed ChemoKine (TECK). Although CCL25 was initially cloned from the thymus, abundant expression was also detected in the small intestine without expression in other tissues such as the liver, lung, and skin.

In the intestinal tract of healthy mice, CCL25 expression is highest in the proximal small bowel (duodenum), decreases towards the distal small bowel (ileum), and is absent or near-absent in the colon. Characterization in the human intestinal tract has been less methodical, although constitutive CCL25 expression appears to be confined to the small intestine, with little or no expression in the stomach.
and colon. In the human small intestine, the cellular source of CCL25 appears to be epithelial cells in the intestinal crypt, and potentially endothelial cells.

CCL25 binds to and signals through a single chemokine receptor, CCR9, of which two alternative splicing variants, CCR9A and CCR9B have been identified. Among circulating leukocytes, CCR9 expression is restricted to a proportion of CD4 and CD8 T cells and activated B cells (Table 1). In mice, CCR9 has been identified on plasmacytoid dendritic cells, although relevant data in humans are lacking. Similarly, while some papers describe CCR9 expression on murine macrophages, human data are lacking. Within peripheral tissues, CCR9 cells are enriched in the human thymus, small bowel, and colon. Intraepithelial lymphocytes are predominantly CD8$, and the majority express surface CCR9.

### Role of CCR9 and CCL25 in intestinal homing

In vitro, CCL25 stimulates CCR9 dependent intracellular signaling, such as intracellular calcium flux and probably recruitment of β-arrestin proteins, and mediates directed cell migration. In vivo, CCR9/CCL25 interactions mediate CD4 and CD8 T cell homing to the small intestine, which is well described in mice (Table 2). Mice genetically deficient for either CCR9 or CCL25 (CCR9$^−/−$ and CCL25$^−/−$ respectively) are healthy, grow to adulthood, and are capable of breeding. However, in the small intestine, where CCL25 is constitutively expressed, the number of CD8$^+$ intraepithelial lymphocytes and CD8$^+$ LP lymphocytes is reduced by approximately 50%. In contrast, the frequency of CD4$^+$ LP lymphocytes is equivalent between wild-type, CCR9$^−/−$, and CCL25$^−/−$ mice suggesting a redundant role of CCR9 and CCL25 in the homeostatic migration of CD4 T cells to the intestine.

During inflammation in mice, CCR9 appears to mediate both CD8 and CD4 T cell homing to the small intestine. In a model of oral antigenic challenge, Wurbel et al used antigen specific CD8 T cells (T cell receptor specific for ovalbumin [OVA]), adoptively transferred into CCL25$^−/−$ mice and orally gavaged with OVA. Following OVA challenge, mice lacking CCL25 had significantly fewer CD8 T cell homing to the LP and epithelium. Similarly, in CD4 T cells, Stenstad et al reported that CCR9$^−/−$ OVA specific CD4 T cells were compromised in their homing to the small bowel following OVA challenge. Collectively these data demonstrate a role for CCR9 in homeostatic CD8 T cell homing, and a role in the homing of both CD4 and CD8 T cells to the small intestine in response to antigenic challenge.

### CCR9$^+$ T cells phenotype and effector function

Peripheral blood CCR9$^+$ T cells are predominantly effector memory cells (CD45RO$^+$), and display a higher frequency of activation markers, including CD25, CD69, OX40, and human leukocyte antigen-DR (HLA-DR) compared to CCR9$^+$ CD8$^+$ T cells. Following in vitro activation, peripheral blood CCR9$^+$ T cells predominantly produce IFN-γ with a minor proportion producing IL-10, IL-2, and IL-4. Similar to circulating cells, CD3$^+$ CCR9$^+$ cells isolated from the small intestine predominantly produced IFN-γ(47.8±4%, n=5). In contrast, IL-10, IL-17, and IL-4 were produced by 7.2±1.8%, 10.1±1.7, and 1.9±0.9% of CCR9$^+$ T cells respectively, demonstrating a preferential Th1 polarization. Collectively, published data demonstrate that the majority of peripheral blood and intestinal CCR9$^+$ cells are Th1 effector cells (producing IFN-γ), with a smaller proportion acting as Th17 effector cells (producing IL-17A) and a minority acting as regulatory T cell and Th2 cells (producing IL-10 and IL-4 respectively).

### CCL25 and CCR9 in inflammation

Traditionally, CCL25 and CCR9 have been regarded as a homeostatic chemokine and chemokine receptor pair,
However, there is increasing evidence that CCL25 can be induced by inflammation and that this chemokine-receptor pair can promote inflammation in particular contexts.

Liver inflammation in primary sclerosing cholangitis

In the healthy liver, CCL25 expression is low or undetected. In human hepatic inflammation, in primary sclerosing cholangitis (PSC), CCL25 expression was detected in the liver, expressed by portal dendritic cells and hepatic sinusoidal endothelial cells. The inflamed liver in PSC was also associated with an increased number of CCR9 positive T cells. Eksteen et al propose that long lived memory gut homing cells that express CCR9 and CCL25 and CCR9 are implicated in PSC, and 75%–90% of patients with PSC also have IBD (mainly UC). However CCL25 mRNA expression in UC and other gastrointestinal or hepatological conditions. However CCL25 is expressed by portal dendritic cells and hepatic sinusoidal endothelial cells. The inflamed liver in PSC was also associated with an increased number of CCR9 positive T cells. Eksteen et al propose that long lived memory gut homing cells that express CCR9 and CCL25 and CCR9 are implicated in PSC, and 75%–90% of patients with PSC also have IBD (mainly UC). However CCL25 mRNA expression in UC and other gastrointestinal or hepatological conditions. However CCL25 is expressed by portal dendritic cells and hepatic sinusoidal endothelial cells. The inflamed liver in PSC was also associated with an increased number of CCR9 positive T cells. Eksteen et al propose that long lived memory gut homing cells that express CCR9 and CCL25 and CCR9 are implicated in PSC, and 75%–90% of patients with PSC also have IBD (mainly UC). However CCL25 mRNA expression in UC and other gastrointestinal or hepatological conditions.

Intestinal inflammation in postoperative ileus

Manipulation of the bowel during surgery or following abdominal trauma frequently leads to ileus, characterized by inflammation and intestinal dysmotility that typically lasts for 24 to 72 hours. The paralysis of peristalsis includes segments of the intestine that have not been operated on or manipulated, suggesting distant or systemic propagation of an inhibitory signal. In a murine model, Engel et al demonstrated that CCR9+ Th1 cells migrated from the small intestine and into the colon, where they induced ileus by IFN-γ mediated activation of resident macrophages. Inhibition of the migration of lymphocytes using fingolimod, an inhibitor of sphingosine-1 receptors, prevented disease suggesting that cell recirculation contributed to the dissemination of disease. Interestingly, in patients who underwent abdominal surgery, the number of CCR9+CD4+ IFN-γ producing cells in the peripheral blood increased 10fold after surgery, suggesting a possible role for CCR9 in human postoperative ileus.

CCL25 and CCR9 expression in IBD

In two murine models of spontaneous ileitis (TNFαARE and SAMP1/Yit models) CCL25 expression increased in the inflamed ileum. And in a murine model of colitis, CCL25 was detected in the inflamed colon following administration of DSS. Characterization of CCL25 expression in IBD is limited. An initial study from Papadakis et al, 2001 analyzed human tissue by IHC, and reported strong CCL25 staining adjacent to areas of T cell infiltration in the small intestine but not the colon. In a study of anti-TNF therapy in IBD, where gene expression was systematically studied before and after treatment, CCL25 expression in the ileum in CD compared to healthy controls was reported, although the difference was not statistically significant. However CCL25 mRNA expression in CD ileitis was increased compared to CD colitis. In this study, CCL25 was not detected in healthy colon, nor in the colon of patients with Crohn’s colitis and UC.

Papadakis et al reported that in active small bowel CD, the proportion of CCR9+CD4+ cells in the peripheral blood was increased compared to healthy controls (8.1% compared to 3.5% respectively); in contrast, patients with CD colitis had equivalent proportions of circulating CCR9+CD4+ T cells. There are as yet no published data on CD8 T cells or on B cells, nor on CCR9 expression in UC and other gastrointestinal or hepatological conditions. However CCL25 and CCR9 are implicated in PSC, and 75%–90% of patients with PSC also have IBD (mainly UC). Therefore the connection between CCL25, CCR9, and UC in PSC patients warrants further investigation; in particular, one might hypothesize that patients with PSC have an altered distribution of CCL25 and CCR9+ cells within the colon.

In CD, the proportion of CCR9+CD3+ cells expressing activation markers CD25, CD69, OX40, CTLA4, CD40L,
Genetic deletion of the TNF-AU rich element (ARE) that
ileum
50
CCR9
79
γ
73
ileum
–
–
+–
–
79
79
Spontaneous, chronic ileitis in discontinuous pattern
–
RAG1
–
Dextran sodium sulfate (DSS) administered in drinking water, inducing
CCX282-B
Colon
Effective in preventing

Table 3

<table>
<thead>
<tr>
<th>Segment of GI affected</th>
<th>CCR9 antagonist (Anti-CCR9 antibody)</th>
<th>Description of model</th>
<th>Disease progression</th>
<th>Disease progression</th>
<th>Disease progression</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colon</td>
<td>DSS colitis</td>
<td>Increased morbidity, survivng mice had higher disease scores.</td>
<td>Similar to wt or more severe disease.</td>
<td>Protected from developing ileitis but could not cure established disease.</td>
<td>Protected from developing ileitis but could not cure established disease.</td>
</tr>
<tr>
<td>Ileum</td>
<td>SAMPI/JY (recombinase activation gene-1 deficient)</td>
<td>More severe disease.</td>
<td>Disease progression similar to wt or more severe disease.</td>
<td>Decreased ileitis but no effect on progression of colonic inflammation.</td>
<td>More severe inflammation of small and large intestine.</td>
</tr>
<tr>
<td>Colon</td>
<td>TNFΔARE</td>
<td>More severe disease.</td>
<td>Disease progression similar to wt or more severe disease.</td>
<td>More severe inflammation of small and large intestine.</td>
<td>More severe inflammation of small and large intestine.</td>
</tr>
<tr>
<td>Colon</td>
<td>RA treated Th17 cells transferred into RAG1−/− mice</td>
<td>More severe disease.</td>
<td>Disease progression similar to wt or more severe disease.</td>
<td>More severe inflammation of small and large intestine.</td>
<td>More severe inflammation of small and large intestine.</td>
</tr>
<tr>
<td>Ileum</td>
<td>CCX201-B (CCR9 antagonist)</td>
<td>Effective in preventing induction of inflammation but could not heal established disease.</td>
<td>More severe disease.</td>
<td>Protected from developing ileitis but could not cure established disease.</td>
<td>Protected from developing ileitis but could not cure established disease.</td>
</tr>
</tbody>
</table>

Abbreviations: CCR9, CC chemokine receptor 9; CCL25, CC ligand 25; DSS, dextran sodium sulfate; GI, gastrointestinal; RA, retinoic acid; RAG1, recombinase activation gene-1; TNF, tumour necrosis factor.

Preclinical use of CCR9 antagonist

The only reported pharmacological antagonist of CCR9 is a compound developed by ChemoCentryx, Inc., Mountain View, CA, USA, initially designated CCX282-B, and later GSK-1605786 or vercirnon. Effects of this inhibitor, which is bio-available in the circulation following oral administration, and which has high specificity for CCR9 with negligible binding to any other chemokine receptor, have been evaluated in murine models of IBD as well as in clinical trials. The published data are reviewed in the next section.

Cell migration and calcium flux, in vitro

Preclinical studies of CCX282-B performed by ChemoCentryx demonstrate potent and specific inhibition of CCR9 mediated intracellular calcium mobilization and cell migration. Measured by chemotaxis, CCX282-B inhibits CCR9 mediated chemotaxis to CCL25 (50% inhibition concentration [IC50] <7 nM), measured in the Molt-4 cells, CCR9 transfected cell lines, primary derived human T cells, and murine and rat thymocytes. Applying a combination of calcium flux and competitive binding assays, CCX282-B did not antagonize nor bind any of the other 18 chemokine receptors, demonstrating CCR9 specificity.

Murine model of ileitis

In vivo, CCX282-B protected TNFΔARE mice from developing spontaneous ileitis. In this model, genetic deletion of the TNF-AU rich element (ARE), an element that normally functions to repress TNF mRNA stability and translation...
to protein, causes mice to have elevated production of TNF; consequently TNEAARE mice develop spontaneous arthritis and ileitis, with intestinal pathology resembling aspects of CD. At weeks 4, 8, and 20 of age, intestinal disease is minimal, peaks, and plateaus respectively. In the ileum, levels of CCL25 were elevated in inflamed tissue. At 12 weeks of age, approximately 80% of TNEAARE mice had moderate to severe intestinal inflammation. Mice treated with CCX282-B (between weeks 2–12, twice daily by subcutaneous injection) had a significant reduction in inflammation, with 30% incidence of moderate disease and no cases of severe disease. The data from these experiments and other preclinical investigation of CCR9 and CCL25 are summarized in Table 3.

Clinical use of CCR9 antagonist
Phase IIb studies of CCX282-B (PROTECT-1)

The clinical efficacy of CCX282-B in CD was tested in a Phase IIb study termed the Prospective Randomized Oral Therapy Evaluation in Crohn’s disease Trial 1 (PROTECT-1), in which a total of 436 patients were enrolled, and randomly assigned to one of four treatment groups: placebo twice daily (n=144); 250 mg CCX282-B once daily (n=98); 250 mg CCX282-B twice daily (n=96); 500 mg CCX282-B once daily (n=97). PROTECT-1 was organized into three study stages:

- Induction period: measuring induction of a clinical response at weeks 8 and 12. Conventional randomized, double-blind, placebo-controlled study testing three different doses of CCX282-B.
- Active period: open-label study in which eligible participants received CCX282-B at a dose of 250 mg twice daily.
- Maintenance period: subjects who had a clinical response following the active period were re-randomized to receive placebo or CCX282-B at a dose of 250 mg twice daily.

The primary endpoint for the induction period of PROTECT-1 was a statistically significant reduction in the CD activity index (CDAI) of 70 points at week 8 of treatment, and this was not met. However, at week 12, significantly more patients on 500 mg daily of CCX282-B had a clinical response compared to placebo (61% versus 47%, respectively, $P=0.039$). At week 12, response rates were similar between patient groups receiving 250 mg CCX282-B once daily or twice daily, or twice daily placebo (56%, 49%, and 47% respectively). This conundrum, of a differential response to a single dose of 500 mg daily, versus 250 mg twice daily, may relate to lower peak serum concentrations of the drug in patients receiving 250 mg twice daily, compared to 500 mg once daily. At week 12, 41% of subjects on CCX282-B were in corticosteroid-free remission, compared to 28% on placebo ($P=0.041$).

Following the 12 week induction period, patients were subsequently offered 4 weeks of active treatment (250 mg twice daily). This period gave all patients the opportunity to receive active treatment from weeks 12–16 of enrollment. At week 16, patients who showed a clinical response defined as a drop in CDAI of ≥70 points were re-randomized to receive placebo or CCX282-B (250 mg twice daily) in the maintenance stage.

The primary endpoint for the maintenance period was maintaining a sustained clinical response at the end of 36 weeks; loss of response was defined as an increase in CDAI >70 points or an increase above 250. In this study CCX282-B 250 mg twice daily was more effective than placebo at maintaining remission: 47% of patients on CCX282-B compared to 31% of placebo ($P=0.012$). Secondary endpoints also suggested some benefit in maintenance, for instance the median C-reactive protein (CRP) levels decreased from 12.6 mg/L to 8.7 mg/L in the CCX282-B patient group, compared to 14.1 mg/L to 12.3 mg/L in the placebo patient group; median CDAI decreased in the CCX282-B patient group (128 to 95) and increased in the placebo group (136 to 146).

Phase III studies of vercirron (SHIELD-1)

Following the outcome of the PROTECT-1 study, further development of CCX282-B was sponsored by GlaxoSmithKline (GSK) plc, Brentford, UK, as part of a partnership alliance with ChemoCentryx Inc. As part of this collaboration, four Phase III trials in CD were initiated, termed Study in Crohn’s Disease Patients Investigating the Efficacy and Safety of an OraLly Dosed CCR9 (SHIELD) 1, 2, 3, and 4. CCX282-B was reformulated and renamed, initially GSK1605786 Formulation A (GSK1605786A), and subsequently vercirron.

SHIELD-1 was a randomized, double blind placebo controlled study to evaluate the efficacy and safety of vercirron 500 mg once daily or 500 mg twice daily over 12 weeks in patients with moderate to severe CD. The SHIELD program was terminated in August 2013, after 605 patients had been recruited into SHIELD-1. Although the data have not yet been published in the literature, they were presented at the American College of Gastroenterology annual conference in October 2013, and showed that there were no significant
differences in clinical response or other endpoints between placebo and either dose of vercirnon. Serious adverse events and withdrawals due to adverse events were similar between the treatment groups. SHIELD-3, which was designed to test efficacy in maintenance was also terminated, and there were insufficient data to determine if there was a positive effect of vercirnon in maintenance.  

The discrepancy in outcome between the Phase IIb PROTECT-1 study and the Phase III SHIELD-1 study remains unexplained, and may be related in part to differences in the patients recruited. For instance, the number of patients previously exposed to anti-TNF treatment in SHIELD-1 was 69%, compared to 26% in PROTECT-1. Unfortunately, although CCX282-B had a positive effect in maintenance in PROTECT-1, maintenance ultimately was not tested in the SHIELD program. 

Safety and tolerability of CCR9 antagonists

In Phase II trials in patients with moderate-to-severe CD (estimated enrollment of 70 individuals), CCX282-B was well tolerated and the incidence of adverse events was comparable between patients assigned placebo and CCX282-B. In the Phase IIb PROTECT-1 trial (n=436), where patients received CCX282-B for up to 52 weeks, the drug was well tolerated: the number of patients reporting adverse events was comparable between treatment groups and placebo, and there was no indication of an increased risk of infection, in the intestine, or systemically.

Conclusion

CCR9+ cells are predominantly Th1 effector memory T cells that are enriched in the small intestine (>60%) and colon (<20%) compared to the peripheral blood (<5%), and are found at an increased frequency in the peripheral blood in some patients with CD. The results of clinical trials antagonizing CCR9 in CD have been variable: the Phase IIb PROTECT-1 study showed efficacy at inducing and maintaining remission compared to placebo, while the more recent SHIELD-1 study did not find any effect in inducing remission. Unfortunately the planned Phase III study to determine if CCR9 blockade could maintain remission was abandoned when the SHIELD program was terminated, although this remains a strong indication for a CCR9 antagonist treatment and an unmet clinical need for patients.

Possible explanations for the different results in PROTECT-1 and SHIELD-1 include differences in patients enrolled. Both studies recruited patients with mild-to-moderate CD, however, the lower limit of CDAI in PROTECT-1 was higher than in SHIELD-1, and the threshold CRP for entry was also higher in PROTECT-1 than in SHIELD-1. Furthermore, the SHIELD-1 study included proportionately more patients who had previously been treated with anti-TNF therapy (69% versus 26%). The trial designs were also different, and the rate of discontinuation was higher in SHIELD-1 compared to PROTECT-1 (25% versus 16%).

Clinical and pre-clinical studies to determine the effect of antagonizing CCR9 in IBD have produced varied and sometimes conflicting results. Targeting CCR9 prevented the induction of ileal disease, as determined in a Th17-specific variant of the RAG-/-/ARE+/- model, and TNF-/-/ARE+/- model. However, in the DSS and RAG-/-/ transfer models of colonic inflammation, disease was either unaffected by, or exacerbated by the lack of CCR9. However, in human studies, there remains the potential benefit of blocking CCR9 to maintain disease remission in CD, and possibly to ameliorate colonic CD and UC.

Although the proportion of CCR9+ cells in the colon, at approximately 20%, is lower than in the small intestine there may be evidence that these cells contribute to colonic IBD. In the PROTECT-1 trial, the subgroup of patients with colonic disease appeared to respond better than patients with isolated small bowel CD. Eberhardson et al recently reported the successful treatment of a patient with active UC, using a technique to remove CCR9 positive cells from the circulation by means of leukocytes with an immobilized CCL25 matrix. These observations, together with the marked benefit of vedolizumab (anti-ɑβ4 integrin) in UC, suggest that targeting CCR9 therapeutically in UC should be considered for investigation.

Similarly, studies to target CCR9 and ɑβ7 integrin in PSC are supported by clinical and experimental data.

To make further progress in delineating the potential clinical role of CCR9 in human disease, detailed mechanistic studies, and well-designed proof-of-concept human trials are now required. These should include studying the interaction between CCR9 and ɑβ7 integrin, and determining the effects of blocking CCR9 on the activation state of circulating and tissue-infiltrating lymphocytes. Maintaining disease remission in CD remains a strong indication for CCR9 antagonist treatment, and any future clinical trials should include patients with UC and with PSC, where CCR9 may play a key role.

Disclosure

Dr Keshav has provided consultancy services for a number of pharmaceutical and healthcare companies including Abbvie, Astra-Zeneca, ChemoCentryx, Dr Falk Pharma,
Ferring, GSK, MSD, Mitsubishi Pharma, Pfizer, Vifor, and Warner-Chilcott, and received research support from Chemo-Centryx, MSD, and Warner-Chilcott. Dr Wendt has received grant support and reagents from ChemoCentryx Inc.

References


